Vanqua Bio Inc. has synthesized C5a anaphylatoxin chemotactic receptor 1 (C5aR; CD88) antagonists reported to be useful for the treatment of autoimmune disease, cancer, infections, and cardiovascular, inflammatory and neurological disorders.
Cogent Biosciences Inc. has disclosed prodrugs and their active metabolites acting as GTPase KRAS and their mutant inhibitors reported to be useful for the treatment of cancer.
Convalife Pharmaceuticals Co. Ltd. and Zhejiang Convalife Pharmaceutical Co. Ltd. have described benzoselenazepine compounds reported to be useful for the respiratory syncytial virus (RSV) infection.
Beijing DP Technology Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently bonded to a Myc proto-oncogene protein (c-Myc)-targeting moiety through a linker reported to be useful for the treatment of cancer, viral infections, and cardiovascular, immunological and cerebrovascular disorders.
The University of California has synthesized proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors reported to be useful for the treatment of cancer, atherosclerosis and stroke.
Hyundai Pharmaceutical Co. Ltd. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors potentially useful for the treatment of cancer.
Contineum Therapeutics Inc. has described lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer, idiopathic pulmonary fibrosis, renal fibrosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH) and scleroderma.
Zai Lab (Shanghai) Co. Ltd. and Zai Lab (US) LLC have divulged spirocyclic compounds acting as transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.
Forx Therapeutics AG has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
RSS